The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

引言：2025年1月16-17日，《柳叶刀-糖尿病与内分泌学》重大报告“临床肥胖症定义和诊断标准”在全球范围内同步发布，迅速获得了全球专家的广泛关注。临床肥胖症的定义和具体内涵是什么？这一新定义又将对肥胖症的诊疗实践、科研（包括药物研发）带来哪些影响 ...

The research found that participants who used the class of drugs which includes Wegovy and Ozempic had a lower risk of 42 ...

This repeated cross-sectional study including 69.2 million obesity management drug dispensed prescriptions revealed an ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...